Skip to content Skip to sidebar Skip to footer

Neuren (ASX:NEU) Crashes 10% on EU Setback: Is This a Buying Opportunity?

Neuren Pharmaceuticals: Is the 10% drop a buy signal? Neuren Pharmaceuticals (ASX: NEU) dropped nearly 10% on Tuesday, falling to A$14.63 from a previous close of A$16.25. The sell-off came…

ByUjjwal Maheshwari

Jan 2026

Biotech Stocks

Neuren Pharmaceuticals (ASX:NEU) Surges 6% on US$700m DAYBUE Target: Time to Buy?

DAYBUE royalties could climb fast if US targets land Neuren Pharmaceuticals (ASX: NEU) jumped 6% on Wednesday after its US partner, Acadia Pharmaceuticals, shared big news at the J.P. Morgan…

ByUjjwal Maheshwari

Dec 2025

Healthcare Stocks

Neuren Pharmaceuticals (ASX:NEU) Gets FDA Approval- Is It a Buy?

Neuren Pharmaceuticals (ASX: NEU) rose 2.5% yesterday after the US FDA approved DAYBUE STIX, a new powder formulation of its Rett syndrome treatment. The stock has surged 47% over the…

ByUjjwal Maheshwari

Apr 2024

Uncategorized

5 ASX Health stocks to add to your porfolio

5 ASX Health Stocks Stuart Roberts from Stocks Down Under discussed the potential promise of biotech, sharing his perspectives about the industry's future amidst changing interest rates. He compares the…

ByMarc Kennis

Oct 2023

Healthcare Stocks

FDA approval: Here’s how ASX biotechs and medtechs obtain it

Last week one of our favourite companies Cyclopharm (ASX:CYC) obtained FDA approval, a goal it had been striving for years to obtain and one that wasn't reached without setbacks along…

ByNick Sundich

Jul 2023

Uncategorized

ASX Life Sciences stocks: Here are 2 of the best!

ASX Life Sciences stocks discussed by Stuart Roberts as interest rates peak What are the Best ASX Stocks to invest in right now? Check our buy/sell tips on the top…

ByMarc Kennis

Feb 2023

Life Sciences

Why did biotech shares underperform in 2022 and will they rebound with a vengence in 2023?

In the past year, biotech shares have performed poorly. Why has this been the case and will things be better in 2023? SIGN UP FOR THE STOCKS DOWN UNDER NEWSLETTER NOW!…

ByNick Sundich

the Kick-ass Multipurpose WordPress Theme

Neuren (ASX:NEU) Crashes 10% on EU Setback: Is This a Buying Opportunity?

Neuren Pharmaceuticals (ASX:NEU) Surges 6% on US$700m DAYBUE Target: Time to Buy?

Neuren Pharmaceuticals (ASX:NEU) Gets FDA Approval- Is It a Buy?

5 ASX Health stocks to add to your porfolio

FDA approval: Here’s how ASX biotechs and medtechs obtain it

ASX Life Sciences stocks: Here are 2 of the best!

Why did biotech shares underperform in 2022 and will they rebound with a vengence in 2023?

Investing in the Year of the Rat

2020, the Golden Year

Market trouble spots to avoid in 2020

Add Your Heading Text Here